OOIR: Observatory of International Research

Papers

(The TQCC of Trends in Cancer is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Turning Cold into Hot: Firing up the Tumor Microenvironment	549
Circular RNAs in Cancer: Biogenesis, Function, and Clinical Significance	391
Senescent Cells in Cancer Therapy: Friends or Foes?	252
3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions	216
Exosomes as a Multicomponent Biomarker Platform in Cancer	175
Clinical Development of BRAF plus MEK Inhibitor Combinations	167
Cancer Epigenetics, Tumor Immunity, and Immunotherapy	166
Necroptosis and tumor progression	160
Targeting Glycosylation: A New Road for Cancer Drug Discovery	150
Targeting EMT in Cancer with Repurposed Metabolic Inhibitors	142
Gut Microbiota in Cancer Immune Response and Immunotherapy	135
MGMT Status as a Clinical Biomarker in Glioblastoma	133
Promoter DNA Hypermethylation and Paradoxical Gene Activation	132
RNA Splicing and Cancer	132
Emerging Mechanisms by which EMT Programs Control Stemness	125
Advanced Prostate Cancer: Treatment Advances and Future Directions	121
Tumour Cell Secretome in Chemoresistance and Tumour Recurrence	97
Molecular Tumor Boards in Clinical Practice	91
Exosomal PD-L1: Roles in Tumor Progression and Immunotherapy	90
Immune Cell-Derived Exosomes in the Cancer-Immunity Cycle	89
Better together: circulating tumor cell clustering in metastatic cancer	88
Extracellular Vesicles in Cancer Detection: Hopes and Hypes	87
Enhancing the Efficacy of Glutamine Metabolism Inhibitors in Cancer Therapy	86
Tumor Plasticity and Resistance to Immunotherapy	86
Precision therapy for RET-altered cancers with RET inhibitors	84

Targeting the DNA Repair Enzyme Polymerase θ in Cancer Therapy	83
Fat and Furious: Lipid Metabolism in Antitumoral Therapy Response and Resistance	77
Targeting ferroptosis in pancreatic cancer: a double-edged sword	76
Tunneling Nanotubes: The Fuel of Tumor Progression?	72
Mitochondrial Stress Response and Cancer	71
Tweak to Treat: Reprograming Bacteria for Cancer Treatment	70
Targeting CAFs to overcome anticancer therapeutic resistance	69
Revisiting the HIF switch in the tumor and its immune microenvironment	68
TRAIL of Hope Meeting Resistance in Cancer	67
Zebrafish Xenografts for Drug Discovery and Personalized Medicine	66
Ferroptosis and Photodynamic Therapy Synergism: Enhancing Anticancer Treatment	64
From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm	61
Targeting SUMO Signaling to Wrestle Cancer	60
Inflammation: the incubator of the tumor microenvironment	59
FTO in cancer: functions, molecular mechanisms, and therapeutic implications	59
Challenges in glioblastoma research: focus on the tumor microenvironment	58
Pharmacological Targeting of IRE1 in Cancer	55
Cirrhosis: A Questioned Risk Factor for Hepatocellular Carcinoma	55
Metabolic Reprogramming in Anticancer Drug Resistance: A Focus on Amino Acids	54
Autophagy Regulates Stress Responses, Metabolism, and Anticancer Immunity	54
The Role of the Microenvironment and Immune System in Regulating Stem Cell Fate in Cancer	53
Drug independence and the curability of cancer by combination chemotherapy	52
Targeting the Mevalonate Pathway in Cancer	51
C1q+ macrophages: passengers or drivers of cancer progression	50
Radiotherapy and immunotherapy: open questions and future strategies	50
Utilizing chemokines in cancer immunotherapy	50
NF-κB in the New Era of Cancer Therapy	48
Targeting the replication stress response through synthetic lethal strategies in cancer medicine	47
Nanotherapeutics for Antimetastatic Treatment	47
Therapeutic targeting of regulatory T cells in cancer	46
Mutagenesis by Microbe: the Role of the Microbiota in Shaping the Cancer Genome	46
The emerging field of oncolytic virus-based cancer immunotherapy	46
Antibody–drug conjugates: in search of partners of choice	45
Liver Inflammation and Hepatobiliary Cancers	45
Coagulome and the tumor microenvironment: an actionable interplay	45
Tumor Innervation: Cancer Has Some Nerve	44
Roles and Regulations of TET Enzymes in Solid Tumors	44
Extracellular and nuclear PD-L1 in modulating cancer immunotherapy	44
T follicular helper cells in cancer	43
Targeting CTGF in Cancer: An Emerging Therapeutic Opportunity	42
Cancer Plasticity: The Role of mRNA Translation	42
Reconciling Non-Genetic Plasticity with Somatic Evolution in Cancer	42
Mechanisms Underlying Recurrent Genomic Amplification in Human Cancers	42
Next-Generation Liquid Biopsies: Embracing Data Science in Oncology	41
Evolution of metastasis: new tools and insights	41
The spectrum of sex differences in cancer	40
Emerging Players in Prostate Cancer–Bone Niche Communication	40
The Hippo Pathway as a Driver of Select Human Cancers	39
Single cell cancer epigenetics	39
Towards the Microbial Production of Plant-Derived Anticancer Drugs	38

How cancer cells make and respond to interferon-I	38
Hypertranscription and replication stress in cancer	38
Drilling for Oil: Tumor-Surrounding Adipocytes Fueling Cancer	38
Nanomedicine-based strategies to target and modulate the tumor microenvironment	38
Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer	36
Cancer of Unknown Primary in the Molecular Era	36
Improving Bioprinted Volumetric Tumor Microenvironments In Vitro	36
Life and Death Decision-Making by p53 and Implications for Cancer Immunotherapy	35
RAC1 as a Therapeutic Target in Malignant Melanoma	34
Technical and biological constraints on ctDNA-based genotyping	34
Dark Side of Cytotoxic Therapy: Chemoradiation-Induced Cell Death and Tumor Repopulation	33
Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us	33
HLA-G/LILRBs: A Cancer Immunotherapy Challenge	33
Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides	32
Tissue architecture in tumor initiation and progression	32
HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy	32
Why Great Mitotic Inhibitors Make Poor Cancer Drugs	32
Understanding the Cause and Consequence of Tumor Heterogeneity	32
Therapeutic Repurposing of Biguanides in Cancer	31
Tele-oncology in the COVID-19 Era: The Way Forward?	31
Tumour microenvironment 3D-modelling: simplicity to complexity and back again	31
PML Nuclear Body Biogenesis, Carcinogenesis, and Targeted Therapy	31
Bispecific Antibodies for Triple Negative Breast Cancer	31
Regulation of extrinsic apoptotic signaling by c-FLIP: towards targeting cancer networks	31
Extracellular ATP and Adenosine in Cancer Pathogenesis and Treatment	30
Stearoyl coenzyme A desaturase-1: multitasker in cancer, metabolism, and ferroptosis	30
Cell death, therapeutics, and the immune response in cancer	29
The Dual Role of High Endothelial Venules in Cancer Progression versus Immunity	28
Mitochondrial DNA is a major source of driver mutations in cancer	28
When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers	27
Metabolic Plasticity of Neutrophils: Relevance to Pathogen Responses and Cancer	27
Pediatric Cancer Models in Zebrafish	27
Decoding endoplasmic reticulum stress signals in cancer cells and antitumor immunity	27
Nanotherapeutics for Immuno-Oncology: A Crossroad for New Paradigms	27
Microfluidics meets 3D cancer cell migration	26
How Comorbidities Shape Cancer Biology and Survival	26
Targeting the Gut Microbiome to Mitigate Immunotherapy-Induced Colitis in Cancer	25
Chromosomal instability and aneuploidy as causes of cancer drug resistance	25
Emerging signaling mediators in the anorexia–cachexia syndrome of cancer	25
Genes that Mediate Metastasis across the Blood–Brain Barrier	25
Beyond Kinases: Targeting Replication Stress Proteins in Cancer Therapy	25
T cell exhaustion in malignant gliomas	25
Building Diverse Mentoring Networks that Transcend Boundaries in Cancer Research	25
DNA Damage Repair Deficiency in Prostate Cancer	25
Age-associated differences in the cancer molecular landscape	24
Tackling PARP inhibitor resistance	24
Human-Derived Model Systems in Gynecological Cancer Research	24
New Roles for Fusobacterium nucleatum in Cancer: Target the Bacteria, Host, or Both?	23
Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma	23
The gut–liver axis: host microbiota interactions shape hepatocarcinogenesis	23
The Mystery of Rap1 Suppression of Oncogenic Ras	23
The Anticancer Potential of T Cell Receptor-Engineered T Cells	22
Neuronal and tumourigenic boundaries of glioblastoma plasticity	22
Cancer cell adaptability: turning ribonucleoprotein granules into targets	22
Exploiting cancer’s drinking problem: regulation and therapeutic potential of macropinocytosis	22
Engineering stem cells for cancer immunotherapy	22
Synthetic Lethal Interactions of RECQ Helicases	22
Immunity beyond cancer cells: perspective from tumor tissue	22
SPAG5: An Emerging Oncogene	22
Cellular and molecular mechanisms of plasticity in cancer	22
Mice Are Not Humans: The Case of p53	21
Lipid in Renal Carcinoma: Queen Bee to Target?	21
Immune response and inflammation in cancer health disparities	21
Group Behavior and Emergence of Cancer Drug Resistance	21
Artificial intelligence-guided discovery of anticancer lead compounds from plants and associated microorganisms	21
Tumor Excision as a Metastatic Russian Roulette: Perioperative Interventions to Improve Long-Term Survival of Cancer Patients	21
GSDME: A Potential Ally in Cancer Detection and Treatment	21
Role of financial toxicity in perpetuating health disparities	21
Emerging mechanisms of telomerase reactivation in cancer	21